Altimmune Q4 GAAP EPS $(0.54) Misses $(0.43) Estimate, Sales $37.00K Up From $(110.00K) YoY
Portfolio Pulse from Benzinga Newsdesk
Altimmune (NASDAQ:ALT) reported Q4 GAAP EPS of $(0.54), missing the $(0.43) estimate, marking a 25.58% increase in losses YoY. Sales rose to $37.00K, up 133.64% from $(110.00K) YoY.
March 27, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Altimmune reported a larger than expected quarterly loss but showed significant sales growth YoY.
While the larger than expected loss may concern investors, the significant increase in sales YoY could indicate potential for future growth, balancing the short term impact on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100